PulseTrendingJournal ClubResearchersJournalsExplore
Instagram
HomeTrendingJournal ClubExplore
Synapse
⌘+K
Synapse
May 21, 2026BMC MicrobiologyOpen Access

In vitro and in vivo activity of colistin-nitroxoline combination against polymyxin heteroresistant carbapenem-resistant Klebsiella pneumoniae

View Full Paper
Ask AI
Bookmark
Share

Authors

XCXin ChenJJJianping JiangXXXiaogang Xu

Discussion

Loading...

Member takes

Overview

Randomized trial evaluates colistin-nitroxoline combination against resistant Klebsiella pneumoniae, suggesting a new treatment strategy.

Key Points

  • This research aims to investigate the effectiveness of the colistin-nitroxoline combination against polymyxin heteroresistant Klebsiella pneumoniae.
  • Evaluated synergy of colistin and nitroxoline against polymyxin heteroresistant strains.
  • Conducted adaptive laboratory evolution experiments to assess resistance emergence.
  • Used a murine peritoneal infection model to test in vivo efficacy.
  • 90.9% prevalence of polymyxin heteroresistance in tested isolates.
  • Combination therapy achieved complete clearance in 75% of isolates at reduced concentrations, compared to monotherapy.
  • Combination therapy reduced mortality to 10% versus 30% for colistin monotherapy, p = 0.30.

Cite This Study

Chen et al. (2026) studied this question.

synapsesocial.com/papers/6a0ea02cbe05d6e3efb5f0e9https://doi.org/10.1186/s12866-026-05150-0
View Full Paper
Ask AI
Bookmark
Share